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ABSTRACT 
The aim of the present study was to formulate and evaluate Almotriptan pellets. Almotriptan controlled release pellets were prepared by 
Solution layering technique by using croscarmellose and povidone in former case and three different polymers HPMC K 100, Ethyl cellulose and 
Eudragit RS 100 as rate controlling polymer in three different ratios like 1:1, 1:1.5 and 1:2 to achieve desired release in later case. Evaluation was 
performed according to the Pharmacopoeia standards including Drug excipients compatibility, Percentage yield, Particle size distribution, Drug 
content analysis and in-vitro release study. The best results were found to be using Almotriptan and Eudragit RS 100 in 1:2 ratios. A broad 
variety of drug release pattern could be achieved by variation of polymers ratios which was optimized to match the target release profile. In 
comparison of in-vitro release studies for different controlled release formulations, F9 releases 98.54% of drug at the end of 12th hour and was 
considered as best formulation. Stability study has shown no significant change in the drug content analysis and in-vitro dissolution study of best 
formulation even after 6 months.  
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INTRODUCTION  
Pelletization can be defined as an agglomeration (size-
enlargement) process that converts fine powders or particles 
of bulk drugs and excipients into small, free-flowing, more or 
less spherical units, and called pellets 1. Granulation is also 
known as pelletization, agglomeration or spheronization, 
and the units obtained referred to as granules, pellets, 
agglomerates or spheroids 2. The general terms 
“granulation” and “pelletization” sometimes used 
synonymously and no clear distinction is made between 
them. Generally, if a size-enlargement process produces 
agglomerates of a size distribution within the range of 0.1 to 
2.0 mm and a high porosity (about 20-50%), the process may 
be called “granulation”, and the resulting agglomerates are 
called granulates 3. Pelletization is often referred to as a size-
enlargement process that involves the manufacture of 
agglomerates with a relatively narrow size range, usually 
with mean size from 0.5 to 2.0 mm, named pellets 4. Pellets 
have free-flowing properties and a low porosity (about 10 
%). The term “spheronization” is more specific, usually 
associated with spherical units formed by a size-enlargement 
process that includes a spheronization step where 
extrudates or agglomerates are rounded as they tumble on a 
rotating frictional base plate, being named spheroids 5. The 
objective of the present work includes To maintain the 
effective drug concentration levels in the blood for a longer 
time, patient compliance by reducing dosing frequency, To 
minimize side effects by maintaining the plasma drug 
concentration at the same level within a therapeutic range 
for the required period 6. 
MATERIALS & METHODS 
The Almotriptan was purchased from Orchid Pvt Ltd, 
Chennai, Excipients like Hydroxy Propyl Methyl Cellulose 
K100   was procured from Himedia Laboratories Pvt. Ltd. 
Mumbai, Eudragit RS 100, Ethyl cellulose, Titanium Dioxide, 
Isopropyl Alcohol, PVP K-30 was procured from S.D. Fine 
Chem. Ltd. Mumbai. All other reagents used were of 
analytical grade. 
Methodology 
Drug-excipients compatibility studies by using FTIR: 
FTIR spectra were recorded with a Thermo Nicolet Japan, in 
the range 450-4000 cm−1 using a resolution of 4 cm−1 and 
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16 scans 7. Samples were diluted with KBr mixing Powder 
and pressed to obtain self-supporting disks. Liquid samples 
formulations were analyzed to form a thin liquid film 
between two KBr disks.  
Formulation of Pellets 
Seal coating: Non-parcel seeds (sugar pellets) (#22/#24) 
were procured from Aadhya Biotech Pvt Ltd. Due to high 
solubility, the sugar spheres immediately get dissolved in 
aqueous media without build-up of sufficient osmotic 
pressure in the core 8. In order, to retard the dissolution rate 
of non-parcel seeds initially coated with 2% (w/w) HPMC E5 
as a seal coat. 
Coating Procedure of Controlled Release Pellets: Slurry of 
Almotriptan with 6% Croscarmellose sodium, 1% povidone 
K-30 (w/w) and add 0.01% tween 80 were dissolved in 
100ml acetone. The  seal coated sugar pellets (Non-parcel 
seeds) (#22/#24) was preheated to about 35o C with gentle 
movement in a pan coater, and then sprayed prepared slurry 
coating % weight build up 30% w/w on sugar pellets while 
spraying the drug solution pan were allowed to rotate for 
about 10 mins until uniform drug loading occurs 9. Spray 
rate, inlet air temperature were adjusted in such a way that 
the core bed reaches a temperature of about 35o C. Over 
wetting of the cores is to be avoided as it may cause 
agglomeration. After a complete quantity of the drug loading 
solution was consumed. The pellets were dried in a tray 
drier at about 45o C to a moisture content of <2%. The dried 
pellets were sized on a sifter to remove agglomerates, 
broken pellets and fine powder. 
Preparation of Coating solution: Almotriptan and HPMC K 
100, Ethyl Cellulose and Eudragit RS 100 were taken in 4 
different ratios 1:1, 1:1.5, and 1:2 as per the table 01 were 
dissolved in 1:1 ratio of methanol and dichloromethane, 
Ethanol and Acetone and Acetone respectively [10]. Finally, 
added 0.1% Tween 80 and 0.5% PEG 400. The composition 
of the coating solution is coded with C1, C2, C3, C4, C5, C6, 
C7, C8, and C9. The solutions were filtered through nylon 
cloth and taken into the spray gun. 
 
Table 1: Composition of Coating Solution 
Coating  
Batches 
Drug: Polymer 
Ratio 
Percentage of  
Coating (%) 
Polymers used 
F1 
F2 
F3 
1:1 
1:1.5 
1:2 
31 
32 
33 
 
HPMC K-100 
 
F4 
F5 
F6 
1:1 
1:1.5 
1:2 
31 
32 
33 
 
Ethyl Cellulose 
 
F7 
F8 
F9 
1:1 
1:1.5 
1:2 
31 
32 
33 
Eudragit RS 100 
 
Coating Procedure: Initially, Seal coated sugar pellets (Non-
parcel seeds) (#22/#24) were taken and preheated to about 
350C with gentle movement in a pan coater, and then 
sprayed prepared Almotriptan, HPMC K 100, Ethyl Cellulose 
and Eudragit RS 100 of 4 different ratios 1:1, 1:1.5 and 1:2 on 
sugar pellets coating % weight buildup for 28%, 29%, 30% 
respectively, while spraying the  solution pan were allowed 
to rotate until uniform drug, and polymer loading occurs 11.  
Table 2: Optimized Process variables for different stages 
of coating 
Process Variables Specifications 
Inlet air temperature (0C) 38-42 
Product bed temperature (0C) 33-37 
Atomization air pressure (bar) 1.2-1.5 
Spray rate (g/min) 10-15 
Pan speed (rpm) 10-15 
 
Evaluation studies 
Percentage yield: All the batches of controlled release 
Almotriptan pellets prepared by pan coating evaluated for 
percentage yield of the pellets 12. The actual percentage 
yields of pellets calculated by using the following formula. 
The % yields of various batches of pellets. 
                            
                                
                                
     
Particle size distribution by sieve analysis: Sieve analysis 
was done by using electromagnetic sieve shaker. A quantity 
of 25 g of pellets was taken on the top sieve, close with a 
plate and run the apparatus with 20 watts power for about 
20 min. After that sieves were weighed and calculated the 
percentage of material remaining on each sieve 13. The 
average particle sizes of the pellets analyzed by simple sieve 
analysis method. The particle sizes of the various batches of 
pellets. 
Drug Content Analysis: Drug content of pellets were 
determined by U.V spectrophotometer, pellets containing 40 
mg equivalent of the drug transferred to a 100ml volumetric 
flask containing pH 7.4 phosphate buffers. For ensuring 
complete solubility sonication done for 30 mins filtered 
through Whatman filter paper 14. The filtrate was analyzed 
by U.V spectrophotometer after appropriate dilution at 227 
nm. The drug content analyses of various batches of pellets.  
In-vitro drug release study: Almotriptan 40mg equivalent 
weight of controlled release (30 mg) pellets were filled in ‘0’ 
size hard gelatin capsule by hand filling capsule Machine and 
drug release studies were carried out for each formulation 
by using Dissolution test apparatus Type I. The data obtained 
from the in-vitro dissolution studies were subjected for 
kinetic treatment to obtain the order of release and the best 
fit model 15. The in-vitro studies of various batches of pellets. 
Pharmacokinetics of Drug Release Mechanism 
The results of in-vitro release profile obtained for all 
formulations were plotted in modes of data treatment as 
follows: 
Zero-order kinetics: The pharmaceutical dosage forms that 
do not disaggregate and release the drug slowly, assuming 
that the area does not change 16 and no equilibrium 
conditions are obtained can be represented by the following 
equation. Qt = Qo + Ko t 
First order kinetics: To study the first order release 
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kinetics the release rate data were fitted to the following 
equation: Log Qt = log Qo + K t / 2.303 
Higuchi model: Higuchi developed several theoretical 
models to study the release of water-soluble and low soluble 
drugs incorporated in semisolids and or solid matrices. 
Mathematical expressions obtained for 17 drug particles 
dispersed in a uniform matrix behaving as the diffusion 
media, the equation is  Q t = KH. t1/2 
Korsmeyer and Peppas Release model: To study this 
model, the release rate data fitted to the following equation F 
= Mt / M = K.tn 
Stability study: The ICH guidelines for evaluation of stability 
data describe when and how extrapolation should consider 
while proposing a retest period for a drug substance or a 
shelf life for a drug product that extends beyond the period 
covered by available data from the stability under the log-
term storage condition 18.  
RESULTS AND DISCUSSION 
Compatibility studies 
 
 
Figure 1: FTIR spectra of Almotriptan 
 
Figure 2: FTIR spectra of Mixture of compound 
 
Table 3: Interpretation data of FTIR spectra of Drug and Excipients 
Almotriptan 
S. No. 
 
Interpretation IR absorption bands (cm-1) 
Characteristic peak Observed peak 
1. (s)= C-H bend 1000-650 666, 685 
2. (s)C-O stretch 1320-1000 1017 
3. (m) C-C stretch (in-ring) 1500-1400 1413 
Mixture of compound 
1. (s)= C-H bend 1000-650 794 
2. (s, b) N-H wag 910-665        823 
3. (m) C-N stretch 1250-1020 1154 
4. (m) C-C stretch (in-ring) 1500-1400 1496 
5. (m) C-H bend 1470-1450 1434 
6. (m) N-H bend 1650-1580 1595, 1626 
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Evaluation Studies 
Percentage yield of pellets: The percentage yields of 
Almotriptan pellets calculated. The percentage yields of 
Almotriptan pellets of controlled release formulations F1 to 
F9 was found to be in the range of 83.12% to 94.97% as 
shown in table 04.  
Drug Content: Percentage drug content of Almotriptan 
pellets of controlled release F1-F9 of all formulations 
determined by UV spectrometric method. The Drug content 
Analysis of controlled release formulations F1 to F9 was 
found to be in the range of 89.44 ± 0.8 % to 99.90 ± 0.3 %. 
The drug content analysis of pellets was found to be within 
the limits as per IP were shown in table 05. 
 
 
Sieve Analysis Method 
Table 4: Particle Size distribution data of Almotriptan Pellets 
Formulation 
Code 
Nominal mesh 
Aperture size 
(µm) 
% Wt. of Pellets 
Retained 
Cumulative % of 
Pellets Retained 
 
F1 
1000 0 0 
850 9 9 
710 83.5 92.5 
355 7 99.5 
 
 
F2 
1000 0 0 
850 8 8 
710 81 89 
355 9 98 
 
 
F3 
 
1000 0 0 
850 8 8 
710 87 95 
355 4 99 
 
F4 
1000 0 0 
850 9 9 
710 85 94 
355 5 99 
 
F5 
1000 0 0 
850 10 10 
710 83.5 93.5 
355 5 98.5 
 
F6 
1000 0 0 
850 6 6 
710 85 91 
355 8 99 
 
 
F7 
1000 0 0 
850 7 7 
710 84 91 
355 7.7 98.7 
 
F8 
1000 0 0 
850 7 7 
710 86 93 
355 6 99 
 
F9 
1000 0 0 
850 8 8 
710 87 87 
355 4 99 
 
Table 5: Yield of pellets and % Drug content Analysis data of prepared pellets 
Formulation Code  Yield of Pellets  Drug content 
F1 83.12 91.22 ± 0.5 
F2 87.26  95.19 ± 0.3 
F3 92.46  92.10 ± 0.6 
F4 87.12  89.44 ± 0.8 
F5 90.18  95.51 ± 0.8 
F6 91.71 91.20 ± 0.2 
F7 85.65  94.60 ± 0.3 
F8 90.56  92.81 ± 0.5 
F9 94.97  99.40 ± 0.3 
Each value represents the mean ± standard deviation (n=3) 
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In-vitro Dissolution Study: In-vitro release studies of all 
Formulations from F1 to F9 were compared, among all the 
formulations F9 shows best release rate with 98.23 % at the 
end of 12hrs in which contains drug and Eudragit RS 100 
ratio 1:2 shown in table 06 & figure 03. 
 
Table 6: In-vitro Drug Release Data Almotriptan controlled release pellets 
Time 
(Hrs) 
Cumulative % Drug Release 
F1 F2 F3 F4 F5 F6 F7 F8 F9 
1 15.65 14.60 10.34 12.32 13.73 19.98 10.13 13.36 18.16 
2 20.12 19.66 23.76 23.65 21.21 28.12 17.56 20.45 26.44 
3 44.68 29.56 38.65 38.73 38.73 33.63 22.87 31.76 35.33 
4 49.56 33.87 43.76 46.36 42.96 48.16 38.45 39.12 49.76 
5 54.53 43.56 48.75 54.76 59.74 53.53 42.21 46.26 54.96 
6 65.32 58.87 53.54 62.26 62.28 68.32 57.87 51.83 65.18 
7 74.97 65.14 58.54 69.27 69.73 72.97 61.65 66.12 71.84 
8 69.74 71.86 63.34 70.56 71.95 79.74 72.63 73.76 78.04 
9 79.83 78.56 68.21 75.21 78.35 83.83 79.18 78.96 81.54 
10 82.43 80.76 73.58 81.29 83.32 87.43 86.28 84.14 88.18 
11 89.51 89.28 78.49 88.29 89.51 91.51 91.86 90.24 91.66 
12 91.28 93.56 88.78 92.28 95.29 96.38 97.64 94.16 98.23 
 
 
Figure 3: In-vitro drug release Profiles of Formulations F1-F9 
 
Kinetic Models Data Analysis: The results of dissolution 
data fitted to various drug release kinetic equations like Zero 
order, First order, Higuchi model and Korsmeyer-Peppas. F1, 
F2, F3, F4, F5, F6, F7, F8, formulations were followed 
Korsemeyer-Peppas with correlation coefficient R2= 0.9689, 
0.9814, 0.9326, 0.9936, 0.971, 0.9576, 0.9781, 0.9613, 
0.9684, 0.9575 and 0.9838 respectively. F9 formulation 
shown both Zero order and Korsmeyer-Peppas models with 
R2=0.9929 and 0.989 respectively, and follows non-fiction 
mechanism and Zero order release with n= 0.957, remaining 
all formulations F1-F8 were found to follow anomalous 
diffusion mechanism with n= 0.5 to 1 when applied to 
Korsmeyer-Peppas kinetic model were tabulated in Table 7. 
 
Table 7: In-vitro drug release kinetics Correlation coefficient data and diffusion exponent data of F1-F9 formulations 
Formulation 
code 
Correlation Coefficient values (R2) Diffusion Exponent 
value (n) Zero order First order Higuchi Korsemeyer-Peppas 
F1 0.9668 0.9538 0.9765 0.9689 0.5443 
F2 0.9814 0.8997 0.9442 0.9331 0.596 
F3 0.9801 0.8562 0.9262 0.9326 0.6255 
F4 0.9526 0.961 0.9831 0.971 0.5051 
F5 0.9576 0.9509 0.9812 0.9726 0.5179 
F6 0.9713 0.9143 0.9775 0.9781 0.5596 
F7 0.989 0.9251 0.9664 0.9684 0.659 
F8 0.9915 0.9009 0.9529 0.9575 0.6916 
F9 0.9929 0.8506 0.9806 0.989 0.957 
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Stability Studies: Stability studies were carried out for 
formulation F9 as per ICH guidelines. In-vitro drug release 
study of the standard are compared with test release for the 
2nd month, 4th month and 6th-month data, and dissolution 
data comparison. It showed good stability and the values 
were within permissible limits as shown in figure 4 & Table 
8.
 
Table 8: Comparison of dissolution data of best formulation F9 subjected to stability study with the standard release 
Time 
(Hrs) 
Cumulative % drug release of best formulation 
Standard After two months After four months After six months 
0 0 0 0 0 
1 38.16 36.86 37.02 35.78 
2 46.44 45.01 44.72 46.03 
3 55.33 54.0 53.76 54.05 
4 59.76 58.07 57.86 57.11 
5 64.96 63.21 62.81 63.04 
6 69.18 67.78 68.14 67.66 
7 73.84 72.10 71.86 73.01 
8 78.04 77.92 76.10 75.88 
9 83.54 82.13 81.90 83.30 
10 87.18 86.88 85.34 85.02 
11 92.66 89.22 91.03 90.93 
12 98.54 97.06 96.58 95.86 
 
 
 
Figure 4: Drug release pattern of the best formulation during stability study for every two months up to 6 months 
 
CONCLUSION  
FTIR Spectroscopy results determined compatibility of the 
Almotriptan, Polymers, and Excipients showed that the 
Almotriptan is compatible with all Polymers. All Nine 
formulations from F1-F9 containing HPMC K 100, 
Ethylcellulose and Eudragit RS 100 in 3 different ratios 
(drug: polymer) 1:1, 1:1.5 and 1:2 prepared. It concluded 
that after in-vitro Dissolution study among nine formulations 
from F1-F9, Combination of Almotriptan and Eudragit RS 
100 F9 formulation ratio 1:2 shown the best result for 12 
hrs. All the formulations were subjected to model fitting 
analysis to know the order and mechanism of drug release 
from the formulations by treating the data according to zero 
– order, first – order, Higuchi and Peppas equations. The data 
clearly shows that the release kinetics revealed that the 
formulation F9 follows both the Zero order and Korsmeyer-
Peppas model with non-fickian diffusion mechanism. 
Stability studies were conducted for best formulation F9 at 
250C/60% and 400C/75% RH for six months at every two 
months interval. The results revealed that no significant 
changes in drug content analysis and in-vitro dissolution 
study, thus indicating that formulation F9 was stable. 
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